ProCE Banner Activity

How I Manage Toxicities Associated With Immunotherapies Used in ALL

Clinical Thought
Gain expert clinical insights from Jae H. Park, MD, on the anticipation, preparation, and management of toxicities associated with immunotherapies used for patients with ALL.

Released: December 17, 2019

Expiration: December 15, 2020

Share

Faculty

Jae H. Park

Jae H. Park, MD

Associate Member
Leukemia Service and Cellular Therapeutics Center
Memorial Sloan Kettering Cancer Center
New York, New York

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

Jazz Pharmaceuticals, Inc.

Pfizer, Inc.

Faculty Disclosure

Primary Author

Jae H. Park, MD

Associate Member
Leukemia Service and Cellular Therapeutics Center
Memorial Sloan Kettering Cancer Center
New York, New York

Jae H. Park, MD, has disclosed that he has received consulting fees from Allogene, Amgen, AstraZeneca, Autolus, GlaxoSmithKline, Incyte, Kite, Novartis, and Takeda.